PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
9804860-1	1998	The equilibrative nucleoside transporters (ENTs) are a newly recognized family of membrane proteins of which hENT1 is the nitrobenzylmercaptopurine ribonucleoside (NBMPR)-sensitive (es) and hENT2 the NBMPR-insensitive (ei) transporter of human cells.	Nitrobenzylmercaptopurine Ribonucleoside	122-162	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	109-114	
27995448-6	2017	Adenosine uptake by hENT1 is competitively inhibited by nitrobenzylmercaptopurine ribonucleoside (NBMPR), nucleosides, deoxynucleosides, and nucleoside-derived anti-cancer and anti-viral drugs.	Nitrobenzylmercaptopurine Ribonucleoside	56-96	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	20-25	
21795683-2	2011	Both transport purine and pyrimidine nucleosides and are distinguished functionally by a difference in sensitivity to inhibition by nanomolar concentrations of nitrobenzylmercaptopurine ribonucleoside (NBMPR), hENT1 being NBMPR-sensitive.	Nitrobenzylmercaptopurine Ribonucleoside	160-200	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	210-215	
19788890-3	2010	Capan-2 cells displayed the lowest levels of (1) extracellular nitrobenzylmercaptopurine ribonucleoside (NBMPR) binding, which represents cell-surface hENT1, (2) FLT and gemcitabine uptake during short (1-45s) and prolonged (1h) periods, and (3) gemcitabine sensitivity.	Nitrobenzylmercaptopurine Ribonucleoside	63-103	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	151-156	
18669604-6	2008	[(3)H]FLT uptake in MCF-7, A549, U251, A498, MIA PaCa-2, and Capan-2 cells was inhibited at least 50% by the hENT1 inhibitor nitrobenzylmercaptopurine ribonucleoside (NBMPR).	Nitrobenzylmercaptopurine Ribonucleoside	125-165	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	109-114	
18462193-1	2008	hENT1 (human equilibrative nucleoside transporter 1) is inhibited by nanomolar concentrations of various structurally distinct coronary vasodilator drugs, including dipyridamole, dilazep, draflazine, soluflazine and NBMPR (nitrobenzylmercaptopurine ribonucleoside).	Nitrobenzylmercaptopurine Ribonucleoside	223-263	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	0-5	
18462193-1	2008	hENT1 (human equilibrative nucleoside transporter 1) is inhibited by nanomolar concentrations of various structurally distinct coronary vasodilator drugs, including dipyridamole, dilazep, draflazine, soluflazine and NBMPR (nitrobenzylmercaptopurine ribonucleoside).	Nitrobenzylmercaptopurine Ribonucleoside	223-263	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	13-51	
17379602-2	2007	Human equilibrative nucleoside transporter 1 (hENT1) is inhibited by nanomolar concentrations of structurally diverse compounds, including dipyridamole, dilazep, nitrobenzylmercaptopurine ribonucleoside (NBMPR), draflazine, and soluflazine.	Nitrobenzylmercaptopurine Ribonucleoside	162-202	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	6-44	
17379602-2	2007	Human equilibrative nucleoside transporter 1 (hENT1) is inhibited by nanomolar concentrations of structurally diverse compounds, including dipyridamole, dilazep, nitrobenzylmercaptopurine ribonucleoside (NBMPR), draflazine, and soluflazine.	Nitrobenzylmercaptopurine Ribonucleoside	162-202	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	46-51	
15905191-5	2005	Inhibition of SLC29A1 by nitrobenzylmercaptopurine ribonucleoside (NBMPR) caused a 33% to 45% reduction of TGN in ALL cells in vitro (P < .006), consistent with the gene expression findings.	Nitrobenzylmercaptopurine Ribonucleoside	25-65	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	14-21	
15486050-7	2005	Exposure to nitrobenzylmercaptopurine ribonucleoside conferred resistance to BR and TR cytotoxicity to hENT1-containing CEM cells, thereby demonstrating the importance of transport capacity for manifestation of cytoxicity.	Nitrobenzylmercaptopurine Ribonucleoside	12-52	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	103-108	
15471562-4	2004	In a highly gemcitabine-sensitive cell line, NCI-H23, the sensitivity to gemcitabine was inhibited by nitrobenzylmercaptopurine ribonucleoside (NBMPR), an inhibitor of hENT1, without significant modulation of hENT1 expression.	Nitrobenzylmercaptopurine Ribonucleoside	102-142	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	168-173	
15205344-6	2004	Application of an inhibitor of SLC29A1, nitrobenzylmercaptopurine ribonucleoside, significantly reduced the potency of these two drugs, indicating that SLC29A1 plays a role in cellular uptake.	Nitrobenzylmercaptopurine Ribonucleoside	40-80	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	31-38	
15205344-6	2004	Application of an inhibitor of SLC29A1, nitrobenzylmercaptopurine ribonucleoside, significantly reduced the potency of these two drugs, indicating that SLC29A1 plays a role in cellular uptake.	Nitrobenzylmercaptopurine Ribonucleoside	40-80	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	152-159	
12820662-5	2003	Whole-cell current measurements showed that application of extracellular nitrobenzylmercaptopurine ribonucleoside (NBMPR), a selective inhibitor of hENT1-mediated transport, had similar effects on whole-cell currents as the application of exogenous adenosine.	Nitrobenzylmercaptopurine Ribonucleoside	73-113	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	148-153